Traders should focus on the August 12 NEO100 Phase 2a readout; the earnings miss is significant but typical for a clinical-stage biotech. The stock's reaction will depend on the clinical data, not the quarterly loss.
Price Chart
Executive Summary
NeOnc reported Q2 2026 EPS of -$0.58, well below the -$0.16 consensus, with net loss widening to $14.2M on higher R&D spending. The company also announced it will present topline Phase 2a NEO100 results on August 12, a key catalyst that may overshadow the earnings miss.
Key Financial Metrics
Key Facts
- EPS of -$0.58 missed consensus of -$0.16 by 262%
- Net loss widened to $14.2M from $5.7M in Q2 2025
- R&D expenses increased to $2.6M from $0.7M year-over-year
- Cash and cash equivalents of $2.0M as of June 30, 2026
- Topline Phase 2a NEO100 results to be presented on August 12, 2026
- UAE IND approvals received for both NEO100 and NEO212 in June 2026
Financial Impact
Net loss of $14.2M, EPS -$0.58 vs consensus -$0.16; operating cash burn of $11.8M in H1 2026
Risk Factors
- Cash burn rate may require near-term capital raise despite undrawn $10M line of credit
- Potential dilution from Mast Hill facility, ATM program, or shelf registration
- Clinical trial failure risk for NEO100 or NEO212
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341858 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $3.27 | awaiting T+60 | — | $3.27 (−0.00%) |
Oct 15, 2026 11d ago | 8-K | $2.70 | awaiting T+60 | — | $3.27 (+21.11%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $3.27 (−1.80%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $3.27 (−4.11%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $3.27 (+9.36%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $3.27 (+10.66%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $3.27 (+10.66%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $3.27 (−30.05%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $3.27 (−40.87%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $3.27 (−5.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers